IceCure reports 70% growth in active US commercial install base after FDA clearance for breast cancer cryoablation

IceCure Medical Ltd.

IceCure Medical Ltd.

ICCM

0.00
  • IceCure reported a 70% increase in its active U.S. commercial install base for ProSense breast cancer cryoablation since FDA marketing authorization in October 2025.
  • Commercial momentum supported by updated ASBrS guidance recommending cryoablation for low-risk breast cancer as a local treatment option.
  • Sales leads from the 2026 SBI symposium and ASBrS annual meeting rose sharply versus the same 2025 events, indicating higher physician demand.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606170825PR_NEWS_USPR_____LN86032) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.